| |
|
|
|
Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results
|
|
Vancouver, BC, August 20, 2018--Aquinox Pharmaceuticals, Inc., a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, provided a corporate update and reported financial results for the second quarter ending June 30, 2018.
|
|
|
|
|
|
|
|
|
|
Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial
|
|
Vancouver, BC, June 132, 2018--Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) announced initiation of dosing in ProShip, a Phase 2 proof-of-concept clinical trial evaluating the efficacy and safety of once-daily rosiptor in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), a urological condition characterized by chronic pelvic pain and voiding symptoms without evidence of urinary tract infection.
|
|
|
|
|
|
|
|
|
|
Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor
|
|
Vancouver, BC, February 13, 2018--Aquinox Pharmaceuticals,Inc. (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced that it has met its enrollment threshold of 300 females in its LEADERSHIP 301 clinical trial of rosiptor (AQX-1125) and remains on track for topline data in the third quarter of 2018.
|
|
|
|
|
|
|
|
|
|
|
|
Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results
|
|
Vancouver, BC, November 28, 2017--Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, reported financial results for the third quarter ending September 30, 2017 and provided a corporate update.
|
|
|
|
|
|
|
|
|
|
Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results
|
|
Vancouver, BC, August 11, 2017--Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, provided a corporate update and reported financial results for the second quarter. Cash, cash equivalents, short-term and long-term investments totaled $131.3 million as of June 30, 2017.
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
